According to a story from globenewswire.com, the biopharmaceutical company Reata Pharmaceuticals, Inc. has recently announced that the company has officially enrolled its first patient in its phase 3 clinical trial.…
According to an article from PM360, Reata Pharmaceuticals has announced that its end-of-Phase 2 meeting with the Food and Drug Administration went according to plan. The American pharmaceutical company based…
According to a story from drugs.com, the biopharmaceutical company Reata Pharmaceuticals, Inc., recently announced that is had recently completed a end of Phase 2 meeting with officials from the US…
According to a story from thenewsreports.com, the biopharmaceutical company XORTX Therapeutics, Inc., recently announced that the company and its partner Cato Clinical Research have received correspondence from the US Food…
What is PKD and ADPKD? PKD (polycystic kidney disease) is a hereditary disease that affects about 1 in 500 persons and typically causes kidney failure in midlife. The most common…
According to a story from businesswire.com, Otsuka Pharmaceutical Europe Ltd recently announced that its product JINARC, also known as tolvaptan, now has an expanded therapeutic indication after a recent approval…
Results from two studies looking at the effects of an experimental drug (bardoxolone) on kidney function in patients with chronic kidney disease (CKD) have been released. One of the studies…
According to a story from Medical Xpress, a long term study testing a treatment for autosomal dominant polycystic kidney disease (ADPKD) has recently concluded. The treatment in question is a…
An ongoing study is investigating how water intake could help treat autosomal dominant polycystic kidney disease, says a recent report. Autosomal dominant polycystic kidney disease (ADPKD) is the most common…
Last week was World Kidney Day! And in fact, the whole month of March is kidney month - so there's no excuse to brush up on some key kidney facts…
© Copyright Patient Worthy
